Clicky

Celcuity Inc.(CELC)

Description: Celcuity, Inc. is a United States-based early stage biotechnology company. The Company develops tests that functionally analyze diseased live cells. The Company has developed CELx Pathway Profile technology, which combines advancements in primary tissue research with a method of measuring a targeted therapy's functional pathway effect on live and diseased patient cells. The Company offers functional cellular analysis platform that assesses the functionality of the disease-related signaling pathways of patient's diseased cells ex vivo and determines whether a drug therapy has the effect on diseased cells. The Company's CELx test is designed to determine whether a pathway is functional to therapeutic intervention without regard to the exact mechanism a patient's tumor may have developed to resist the therapeutic effect. The Company’s diagnostic approach helps to identify cancer subtypes.


Keywords: Biotechnology Cancer Biology Stem Cell Cell Biology Targeted Therapy Signal Transduction Cell Signaling Drug Therapy Systems Biology Patient's Tumor

Home Page: www.celcuity.com

CELC Technical Analysis

16305–36th Avenue North
Minneapolis, MN 55446
United States
Phone: 763 392 0767


Officers

Name Title
Mr. Brian F. Sullivan Co-Founder, Chairman & CEO
Dr. Lance G. Laing Ph.D. Co-Founder, Chief Science Officer, VP, Sec. & Director
Ms. Vicky Hahne Chief Financial Officer
Dr. John R. MacDonald Dabt, Ph., Ph.D. Sr. VP of R&D
Ms. Sheri Smith Acting Head of Clinical Operations
Mr. Igor Gorbatchevsky M.D. Chief Medical Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 3.3317
Price-to-Sales TTM: 0
IPO Date: 2017-09-20
Fiscal Year End: December
Full Time Employees: 39
Back to stocks